LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects.
CD8+ T cells
cancer
immunotherapy
melanoma
oncolytic peptide
sarcoma
Journal
Cell stress
ISSN: 2523-0204
Titre abrégé: Cell Stress
Pays: Austria
ID NLM: 101718867
Informations de publication
Date de publication:
14 Oct 2019
14 Oct 2019
Historique:
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
epublish
Résumé
LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of cancer that typically resist current treatment options and to better understand the drug's mode of action
Identifiants
pubmed: 31799501
doi: 10.15698/cst2019.11.204
pii: CST0179E133
pmc: PMC6859426
doi:
Types de publication
Journal Article
Langues
eng
Pagination
348-360Informations de copyright
Copyright: © 2019 Liao et al.
Déclaration de conflit d'intérêts
Conflict of interest: This project was supported by Lytix Biopharma. M.J.P. has served as a consultant for Baxalta, Deciphera Pharmaceuticals, FORMA Therapeutics, Incyte Pharmaceuticals, Jounce Therapeutics, KSQ Therapeutics, Secarna, Siamab, and Syndax; these commercial relationships are unrelated to the current study. R.W. is a cofounder of T2 Biosystems, Lumicell, Accure Health, and VisEn Medical (acquired by Perkin Elmer) and advises Moderna, Alivio Therapeutics, Tarveda Therapeutics, and BioAnalytix; these relationships are unrelated to the current study.
Références
Cancer Immunol Immunother. 2014 Jun;63(6):601-13
pubmed: 24676901
Cancer Res. 2017 Aug 1;77(15):4146-4157
pubmed: 28536278
Nat Rev Cancer. 2016 Jul;16(7):447-62
pubmed: 27339708
Future Med Chem. 2017 Aug;9(12):1339-1344
pubmed: 28490192
Nat Med. 2007 Aug;13(8):992-7
pubmed: 17676052
JCI Insight. 2019 May 21;4(13):
pubmed: 31112524
Oncotarget. 2015 Sep 29;6(29):26599-614
pubmed: 26378049
Theranostics. 2018 Nov 12;8(21):5842-5854
pubmed: 30613266
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Sci Immunol. 2018 Sep 7;3(27):
pubmed: 30194240
J Med Chem. 2016 Apr 14;59(7):2918-27
pubmed: 26982623
Oncoimmunology. 2017 Jun 16;6(8):e1338236
pubmed: 28920000
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Sci Transl Med. 2017 May 10;9(389):
pubmed: 28490665
Science. 2017 Dec 1;358(6367):
pubmed: 29191879
Oncotarget. 2015 Oct 27;6(33):34910-23
pubmed: 26472184
Cell Death Differ. 2016 Jun;23(6):1004-15
pubmed: 27082453
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Neoplasia. 2009 May;11(5):459-68, 2 p following 468
pubmed: 19412430
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Science. 2016 Apr 8;352(6282):242-6
pubmed: 26989197
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Oncoimmunology. 2014 Jun 25;3:e29181
pubmed: 25083333
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848